Celldex Therapeutics Inc expected to post a loss of 59 cents a share - Earnings Preview

Celldex Therapeutics

24/02/2023 14:00

* Celldex Therapeutics Inc  CLDX.OQ   CLDX.O  is expected
to show
a fall in quarterly revenue when it reports  results on February
27 (estimated). 
    * The Hampton New Jersey-based  company is expected to
report  a
20.7% decrease in revenue to $264 thousand from $333 thousand a
year ago, according to the mean estimate from 5 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Celldex
Therapeutics Inc
is for a loss of 59 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Celldex
Therapeutics Inc is $64.5​, above​ its last closing price
of $41.50. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.57       -0.58      -0.57     Beat    1.2
 Jun. 30 2022  -0.51       -0.51      -0.59     Missed  -15.7
 Mar. 31 2022  -0.45       -0.45      -0.49     Missed  -7.9​
 Dec. 31 2021  -0.42       -0.42      -0.43     Missed  -3.2
 ​​Sep.        -0.35       -0.36      -0.45     Missed  -25
 30 2021                                                
 Jun. 30 2021  -0.40       -0.40      -0.34     Beat    15​
                                      -0.42             
 Dec. 31 2020              -0.37      -0.55     Missed  -50
 This summary was machine generated February 24 at 14:00 GMT. 
All figures in US dollars  unless otherwise stated